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umc.nl (Abstract Background: Tyrosine kinase inhibitors treatment in responding chronic myeloid
leukaemia (CML) patients is generally continued indeﬁnitely. In this randomised phase II
trial, we investigated whether CML patients in molecular response4.5 (MR4.5, quantitative
reverse-transcription polymerase chain reaction (RQ-PCR)) after previous combination ther-
apy with imatinib and cytarabine may discontinue imatinib treatment safely.
Patients and methods: Thirty-three patients from the HOVON 51 study with an MR4.5 for at
least 2 years who were still on imatinib treatment were randomised between continuation of
imatinib (arm A, n = 18) or discontinuation of imatinib (arm B, n = 15).
Results: After a median follow up of 36 months since randomisation, 3 patients (17%) in arm
A and 10 patients (67%) in arm B had a molecular relapse. All 3 relapsing patients in arm Alsevier Ltd. All rights reserved.
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N. Thielen et al. / European Journal of Cancer 49 (2013) 3242–3246 3243had also stopped imatinib after randomisation. All but one relapsing patient relapsed within 7
months after discontinuation of imatinib. The molecular relapse rate at 12 and 24 months
after randomisation was 0% and 6% (arm A) and 53% and 67% (arm B) respectively. As-trea-
ted analysis revealed 56% and 61% relapses at 1 and 2 years since cessation in patients who
discontinued imatinib, in contrast to 0% of patients who continued imatinib. All evaluable
patients remained sensitive to imatinib after reinitiation and regained a molecular response.
Conclusion: Our data suggest that discontinuation of imatinib is safe in patients with durable
MR4.5.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
The introduction of imatinib, a decade ago, has
dramatically improved the outlook of chronic myeloid
leukaemia (CML) patients. In the International
Randomised Study of Interferon versus STI571 (IRIS
study), high rates of haematologic, cytogenetic and
molecular responses were seen. Moreover, an impressive
reduction of patients progressing to more advanced
stages of the disease was observed.1,2
Until now, responding patients are supposed to con-
tinue tyrosine kinase inhibitors (TKIs) indeﬁnitely. Nev-
ertheless, several studies have recently shown that
around 40% of the patients with a long-lasting deep
molecular response or undetectable BCR-ABL1 can stop
imatinib without subsequent molecular relapse.3–6 In
addition, published studies suggest that all relapsing
patients are sensitive to imatinib reinitiation.3,5,7–9
These observations justiﬁed an amendment to our
previously published feasibility and eﬃcacy study of
imatinib in combination with cytarabine.10,11 In this
HOVON 51 study 162 patients were treated with esca-
lating doses of imatinib and cytarabine, a combination
hypothesised to result in deeper molecular responses.
Indeed, a relatively high cumulative MR4.5 rate of 53%
at 5 years was achieved.10,11 We set out to investigate
if these deeper molecular responses would translate in
higher chances of remaining in remission after discontin-
uation of imatinib. Thus, we here report on an amend-
ment of the HOVON 51 study, randomising patients
with a durable MR4.5 between imatinib continuation
or discontinuation.
2. Patients and treatment
In the HOVON 51 study, patients received escalating
doses of imatinib (200, 400, 600 or 800 mg) in combina-
tion with escalating doses of cytarabine (200 or
1000 mg/m2 days 1–7 during two cycles) according to
the study protocol. Imatinib maintenance consisted of
imatinib 400, 600 or 800 mg. The study protocol and
results have previously been published.10,11 Patients
were eligible for randomisation between continuation
or stopping imatinib when they had attained a MR4.5
on protocol for at least 2 years. MR4.5 was deﬁned as
>4.5 log reduction of BCR-ABL1 by quantitativereverse-transcription polymerase chain reaction (RQ-
PCR) and conﬁrmed by a negative real-time polymerase
chain reaction (RT-PCR). Informed consent was
obtained from all patients in accordance with the Decla-
ration of Helsinki. The ethics committees of the partici-
pating institutions approved the study.
Patients were centrally randomised 1:1 between both
arms. Patients randomised to discontinue imatinib
immediately stopped imatinib. Following discontinua-
tion of imatinib patients underwent monthly RQ-PCR
for BCR-ABL1 on peripheral blood and 2-monthly
RQ-PCR for BCR-ABL1 on bone marrow during the
ﬁrst half year. After the ﬁrst 6 months peripheral blood
and bone marrow testing were performed every 2 and 3
months respectively, until 1 year after discontinuation.
Thereafter, RQ-PCR for BCR-ABL1 was performed
on peripheral blood every 3 months and on bone mar-
row every 6 months. Cytogenetic evaluations were per-
formed at 2, 4 and 6 months and at 3 months intervals
thereafter until 1 year after discontinuation, thereafter
at least every 6 months. Patients randomised to continue
imatinib underwent peripheral blood RQ-PCR for
BCR-ABL1 every three months indeﬁnitely. According
to the original HOVON 51 protocol, bone marrow cyto-
genetics was performed every 6 months during the ﬁrst
year and once a year thereafter.
In case the RQ-PCR for BCR-ABL1 result became
positive (i.e. <4.5 log reduction) in patients who had
stopped imatinib, this was conﬁrmed by a second RQ-
PCR for BCR-ABL1. When this second PCR was also
positive, patients restarted imatinib maintenance
therapy in the same dose as they had received before
discontinuation of the drug. For the HOVON 51 design
and ﬂow diagram of this study we refer to the Supple-
mental Files 1 and 2.
3. Methods
The molecular response was centrally assessed at the
Erasmus University Medical Centre in Rotterdam using
BCR-ABL1 real-time quantitative reverse-transcription
polymerase chain reaction (RQ-PCR). RQ-PCR was
performed as previously published.10,11 A laboratory-
speciﬁc conversion factor to the international scale (IS)
was acquired via the European Treatment and Outcome
Study (EUTOS) for CML.12 The quality of the
Fig. 1. Time from randomisation until loss of MR4.5.
3244 N. Thielen et al. / European Journal of Cancer 49 (2013) 3242–3246BCR-ABL1 real-time quantitative PCR quantiﬁcation
was monitored by the Dutch Network for Molecular
Diagnostics of Haematologic malignancies (MOD-
HEM, website www.modhem.nl) by means of annual
quality control rounds.
Deﬁnitions of molecular responses are as described
previously.10
4. Deﬁnition of end-points and statistical considerations
The primary objective of the study was to evaluate
whether patients in a long lasting MR4.5 after induction
with cytarabine and imatinib maintenance treatment
could discontinue imatinib safely.
The primary end-point of this study was the molecu-
lar relapse rate at 6 months after discontinuation for
patients in arm B. Our aim was to estimate the 6-
months’ molecular relapse rate with a standard error
of 10%, for which 25 patients in arm B would be
required. Patients were randomised 1:1. Therefore 25
patients would also be included in arm A. The study
was not designed nor powered to compare the results
between the two treatment arms. Secondary end-points
were the rate and time to complete molecular response
after resuming imatinib in patients with a molecular
relapse after discontinuation, the rate of progression to
haematological relapse and progression to accelerated
phase and blast crisis in patients who discontinued
imatinib. All analyses were performed according to the
intention-to-treat principle. For reasons of clarity,
results of a per-protocol analysis are also given.
The molecular relapse rate at 6 and 12 months was esti-
mated per treatment arm using the actuarial method of
Kaplan andMeier, and the corresponding 95% conﬁdence
interval (CI) was calculated. A Kaplan–Meier curve was
generated to illustrate molecular relapse over time.
5. Results
The results of the HOVON 51 study have been
described previously.10,11 Of 162 included patients, 33
patients from nine centres with persistent MR4.5 were
enrolled in this stop study between August 2008 and
April 2011. Eighteen patients were randomised to con-
tinue imatinib therapy (arm A) and 15 patients were ran-
domised to discontinue imatinib therapy (arm B). The
randomisation was continued until 2011, when the
results of the other stop studies became available and
an amendment of the protocol was accepted wherein
all patients in long-lasting MR4.5 were allowed to stop
imatinib. Therefore we did not include 50 patients as
outlined in our previous statistical plan. The data were
analysed as available at April 2013. Median follow-up
since randomisation is 36 months (range 8–54). Patient
characteristics are shown in Supplemental File 3. Med-
ian time to reach MR4.5 was 20 months. Until now, 3
patients (17%) in arm A and 10 patients (67%) in armB experienced a molecular relapse (Fig. 1). All patients
relapsing in arm A (at 9, 13 and 20 months after ran-
domisation) had discontinued imatinib already. The
time elapsed between stopping imatinib and loss of
MR4.5 for these 3 patients was 1, 3 and 3 months. An
additional 4 patients in arm A also discontinued imati-
nib but did not relapse. The 10 molecular relapses in
arm B occurred at a median interval of 3 months (range
1–12) after randomisation. All but one patient in arm B
relapsed within 7 months after randomisation. Accord-
ing to the ITT analysis, this results in a molecular
relapse rate of 0% and 53% (95% CI 31–79%) at 6
months, 6% (95% CI 1–39%) and 60% (95% CI 37–
84%) at 12 months and 21% (95% CI 7–52%) and 67%
(CI 44–88%) at 24 months in arm A and arm B respec-
tively. As-treated analysis however reveals 0% relapses
in patients who continued maintenance, while for the
patients who discontinued maintenance, relapse rates
at 12 and 24 months since discontinuation were 56%
(95% CI 37–77%) and 61% (42–81%), respectively. Five
relapsing patients also had a cytogenetic relapse, one in
arm A (minimal cytogenetic response) and 4 in arm B
(all partial cytogenetic response). All patients in arm A
who continued the allocated imatinib treatment
remained in MR4.5. No patient progressed to accelerated
phase or blast crisis. Table 1 shows the characteristics of
the relapsing and non-relapsing patients restricted to the
discontinued patients. Of the 5 patients in arm B who
discontinued imatinib but were relapse free, all of them
showed a stable MR4.5. Of all 13 patients who lost
MR4.5, 9 restarted with imatinib in the same dose as they
received before the discontinuation of imatinib. Two
patients who took 600 mg imatinib before discontinua-
tion, restarted at a dose of 800 mg imatinib, but in one
patient this dose was decreased to 600 mg after 6.5
months. Another patient who took 600 mg imatinib
before discontinuation, restarted at a dose of 400 mg
imatinib and one patient started with nilotinib.
All 13 patients regained a MR4.5 after median 6
months (range 2–15) since reinitiation of imatinib or
Table 1
Patient characteristics according to relapse or no relapse in the group who discontinued imatinib.
Relapsed after discontinuation
No Yes Total
Total 9 13 22
Study arm
A: Continue 4 3 7
B: Stop 5 10 15
Sex (no)
Male 7 4 11
Female 2 9 11
Sokal score (no)
Low 4 6 10
Intermediate 2 5 7
High 2 2 4
Unknown 1 0 1
Duration of imatinib therapy (months)
Median 111 92 98
Range 90–137 65–125 65–137
Time to CMR (months)
Median 12 27 20
Range 7–26 7–60 7–60
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in arm A because of refusal of imatinib and adverse
events and 1 in arm B because of protocol violation.
6. Discussion
To our knowledge, this is the ﬁrst randomised trial
regarding the discontinuation of imatinib in ﬁrst chronic
phase CML patients having achieved a durable and sta-
ble MR4.5. Our results are encouraging: 33% of the
patients in arm B who discontinued imatinib after at
least 2 years of MR4.5 did not relapse and have a
long-time persistence of MR4.5 after therapy cessation
while 67% of the patients had a molecular relapse, all
occurring within 7 months after cessation of imatinib.
When not taking into account the intention-to-treat
principle, the relapse percentage of the patients who
actually discontinued imatinib was 56% at 12 months.
Nevertheless and of great importance, after recommenc-
ing imatinib treatment, all evaluable relapsing patients
regained an MR4.5.
Our results are comparable with previous non-ran-
domised stopping trials, although others included many
patients who were pretreated with interferon alpha,
while our patients had all received cytarabine.4–6,8,9,13
It is unclear whether the addition of these drugs has con-
tributed to the persistence of response after stopping
imatinib.5,14–16
Altogether, results of the diﬀerent stop studies are
promising. Nevertheless, a major concern is that cessa-
tion of imatinib might lead to genomic instability due
to re-exposure of leukaemic stem cells (LSCs) to BCR-
ABL1 kinase activity and safety should therefore be a
major issue in these studies.17 Our and other studiesshow that all evaluable relapsing patients swiftly regain
at least a major molecular response (MMR) after rein-
troduction of imatinib.3,5,7–9 indicating that clonal shifts
towards resistance against imatinib are unlikely to occur
during discontinuation. However, longer follow up of
these patients and larger studies are needed. Due to
the limited size of the study, we were unable to deter-
mine risk factors for relapse.
It is remarkable that a subset of patients did not
relapse after imatinib discontinuation, as, in vitro, imati-
nib or any other TKI seem to be unable to eradicate
LSCs.18–20 Indeed, several studies have shown that even
in longstanding deep molecular responses with or with-
out TKI treatment, BCR-ABL1 containing cells can still
be detected and that they have persistent stem cell
capacity.13,21 Further studies focusing on discontinua-
tion of imatinib, but also of nilotinib and dasatinib, will
be highly relevant to unravel the possible molecular and
immunologic mechanisms underlying sustained molecu-
lar responses or relapse. But most important for clinical
practice, these studies have to deﬁne predictive factors
for successful TKI discontinuation.
In conclusion, although imatinib treatment was pre-
viously expected to be life-long, our data suggest that,
under close PCR monitoring, discontinuation of imati-
nib is safe in CML patients with a long-lasting MR4.5.
A signiﬁcant part of patients will remain in MR4.5, while
relapsing patients maintain sensitivity to imatinib.
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